Rezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual Meeting

Rezolute to Participate in Upcoming Investor Conferences

Rezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor Hyperinsulinism

Rezolute’s stock up on interim Phase III tumour HI data

Rezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine Society

Rezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine Society

Rezolute to Participate in the BTIG Virtual Biotechnology Conference

Rezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital Hyperinsulinism

Rezolute FDA Review Continues After Phase 3 sunRIZE Study Missed Primary Endpoint

Sector Update: Healthcare Stocks Softer Late Afternoon